Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06572228 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
A Phase 4 study of Asthma, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06572228: Recruiting Phase 4 study of Asthma, sponsored by Regeneron Pharmaceuticals.
NCT06572228 is a Phase 4 study of Asthma that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 250 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06572228, a Phase 4 study of Asthma, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA. The study is also looking at: • What side effects may happen from taking dupilumab
Conditions Studied
Interventions
- DRUG dupilumab
- DRUG Matching Placebo
- DRUG ICS/LABA
Study Locations (20)
California
- Kern Research, Inc - Bakersfield
- Modena Allergy & Asthma, Inc. - La Jolla
- Antelope Valley Clinical Trials - Lancaster
- Ark Clinical Research - Long Beach - Long Beach
- Newport Native Md, Inc. - Newport Beach
- Childrens Hospital of Orange County Main Campus - Orange
- Riviera Allergy Medical Center - Redondo Beach
- Raffi Tachdjian MD, Inc. - Santa Monica
- Bensch Clinical Research - Stockton
- Integrated Research of Inland, Inc. - Upland
- Allianz Research Institute - Westminster
Illinois
- Northwestern University - Chicago
- Sneeze Wheeze and Itch Associates - Normal
- Asthma and Allergy Center of Chicago - River Forest
- NorthShore University Health System - Skokie
Florida
- St Francis Medical Institute - Clearwater
- Florida Lung, Asthma and Sleep Specialists (FLASS) - Celebration - Kissimmee
- Clinical Site Partners, LLC DBA Flourish Research - Winter Park
Colorado
- National Jewish Health - Denver
Idaho
- Treasure Valley Medical Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-08-26 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
What NCT06572228 shows while recruiting
NCT06572228 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which dupilumab is the first listed.
NCT06572228 names 20 study sites across 5 states, led by California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT06572228 about?
NCT06572228 is a clinical study titled "Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma". This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their cu...
What is the current status of trial NCT06572228?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2024-08-26. Estimated completion is 2026-12-31.
What conditions does trial NCT06572228 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06572228?
The interventions under investigation include: dupilumab (DRUG), Matching Placebo (DRUG), ICS/LABA (DRUG).
Who is sponsoring clinical trial NCT06572228?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06572228 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06572228's enrollment target sits among peer trials
250 139th of 374 higher than 236 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Individualizing Treatment for Asthma in Primary Care (Full Study)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI